CTLA4 and neoplasm: Ipilimumab is an FDA-approved human monoclonal antibody that blocks an immune checkpoint molecule called cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) leading to increased antitumor activity of tumor-specific T-cells and improved survival in patients with melanoma [1].